Commonwealth Equity Services
KZIA

Commonwealth Equity Services’s Kazia Therapeutics KZIA Stock Holding History

Commonwealth Equity Services’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-610
Closed -$13K – 4160
2024
Q3 		$13K Buy
+610
New +$12.2K ﹤0.01% 4024

Other funds holding KZIA

MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Commonwealth Equity Services's KZIA Position: Q4 2024 in Review

Commonwealth Equity Services sold out of Kazia Therapeutics (KZIA) in Q4 2024, closing a stake of 610 shares — an estimated $13K sold.

Commonwealth Equity Services first reported a position in KZIA in Q3 2024 and held it in 1 quarter. The position peaked at $13K in Q3 2024. 10 funds tracked by Wall St. Rank hold KZIA as of Q4 2024.

  • Commonwealth Equity Services reported no remaining Kazia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Commonwealth Equity Services sold 610 Kazia Therapeutics shares in Q4 2024, an estimated $13K.
  • Commonwealth Equity Services first reported a position in Kazia Therapeutics in Q3 2024 and held it in 1 quarter.
  • Commonwealth Equity Services's Kazia Therapeutics position peaked at $13K in Q3 2024.
  • 10 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q4 2024.

Based on Commonwealth Equity Services's 13F filing for Q4 2024, filed 10 Feb 2025.